% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tessonnier:294554,
      author       = {T. Tessonnier$^*$ and D. I. Filosa and C. Karle$^*$ and F.
                      Baltazar$^*$ and L. Manti and L. Glimelius and T. Haberer
                      and A. Abdollahi$^*$ and J. Debus$^*$ and S. Mein$^*$ and I.
                      Dokic$^*$ and A. Mairani$^*$},
      title        = {{F}irst {D}osimetric and {B}iological {V}erification for
                      {S}pot-{S}canning {H}adron {A}rc {R}adiation {T}herapy
                      {W}ith {C}arbon {I}ons.},
      journal      = {Advances in radiation oncology},
      volume       = {9},
      number       = {12},
      issn         = {2452-1094},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2024-02329},
      pages        = {101611},
      year         = {2024},
      note         = {#EA:E050#LA:E210#},
      abstract     = {Spot-scanning hadron arc radiation therapy (SHArc) is a
                      novel delivery technique for ion beams with potentially
                      improved dose conformity and dose-averaged linear energy
                      transfer (LETd) redistribution. The first dosimetric
                      validation and in vitro verification of carbon ion arc
                      delivery is presented.Intensity-modulated particle therapy
                      (IMPT) and SHArc plans were designed to deliver homogeneous
                      physical dose or biological dose in a cylindrical polymethyl
                      methacrylate (PMMA) phantom. Additional IMPT carbon plans
                      were optimized for testing different LETd-boosting
                      strategies. Verifications of planned doses were performed
                      with an ionization chamber, and a clonogenic survival assay
                      was conducted using A549 cancer lung cell line.
                      Radiation-induced nuclear 53BP1 foci were assessed to
                      evaluate the cellular response in both normoxic and hypoxic
                      conditions.Dosimetric measurements and clonogenic assay
                      results showed a good agreement with planned dose and
                      survival distributions. Measured survival fractions and foci
                      confirmed carbon ions SHArc as a potential modality to
                      overcome hypoxia-induced radioresistance. LETd-boosted IMPT
                      plans reached similar LETd in the target as in SHArc plans,
                      promising similar features against hypoxia but at the cost
                      of an increased entrance dose. SHArc resulted, however, in a
                      lower dose bath but in a larger volume around the target.The
                      first proof-of-principle of carbon ions SHArc delivery was
                      performed, and experimental evidence suggests this novel
                      modality as an attractive approach for treating hypoxic
                      tumors.},
      cin          = {E050 / E210 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)E210-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39534427},
      pmc          = {pmc:PMC11555336},
      doi          = {10.1016/j.adro.2024.101611},
      url          = {https://inrepo02.dkfz.de/record/294554},
}